Skip to main content
Premium Trial:

Request an Annual Quote

Just Do It Already, Pfizer

Derek Lowe, like many, is waiting to see how the Pfizer layoffs will pan out. Planning for months now to cut research staff, Pfizer still hasn't lowered the ax, but Lowe predicts that the changes will be "quite profound in chemistry. Pfizer seems to be dividing its chemists up into people who think up molecules, and people who make them, with no real overlap," he writes at In the Pipeline. He also predicts that outsourcing will be taken to a whole new level. The worst part, though, is having to sit and wait for the news for months on end, he says, adding, "the way this is being done has not reflected well on the company's management and how it treats its employees."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.